Leaders of failed Alzheimer’s drug trial suggest a higher dose would work.  Further analyses of data from the halted SCarlet RoAD study of the anti-amyloid drug gantenerumab for Alzheimer’s disease suggest that the agent may have some benefit, especially at higher doses than those tested in the trial, researchers reported here. {read more here}